IQVIA clinical research

Find and learn about IQVIA clinical trials and patient communities. Plus, sign up for alerts for new clinical trials and community updates.

Let’s work together to find a way to prevent COVID-19

Study participants will receive coronavirus 2019 (COVID-19) study-related care at no cost.

Clinical research studies to learn about potential new vaccines, including boosters and vaccines against variants of the virus, are enrolling.

See if you qualify for a vaccine research study

Help us find a way to speed up recovery from COVID-19 and reduce the need for hospital care.


See if you qualify for a treatment research study

Clinical studies continue during the COVID-19 pandemic

The majority of clinical studies continue to move forward during the COVID-19 pandemic. Study teams are working closely with participants to ensure patient safety while meeting trial goals for successful clinical research.

Most healthcare facilities remain open in most areas, however many of them have changed their hours and have new procedures to ensure safety for trial participants.

Some study doctors may suggest televisits (phone or video call) so that patients can still attend scheduled visits without having to leave home.

If you are currently enrolled in a clinical trial, be sure to speak with your doctor about the status of your study and discuss any changes that have been put in place due to the novel coronavirus, SARS-CoV-2.

Participating in clinical research

Clinical research is vital to the development of new medical treatments. Clinical research is the study of medical conditions in people, which enables researchers to gather valuable knowledge to advance medical insights around the world. Without clinical research trials, advances in healthcare and medical treatments would not be possible.

Find out more about clinical trials >

Explore our patient communities

Gain insights into:

  • health conditions that interest you
  • related clinical research
  • experiences from other patients

Explore posts from across ClinicalResearch.com.
Filter by your area of interest.

For Potential Participants

Children Diagnosed with Type 2 Diabetes at Risk for Serious Complications in Their 20s

Youth with type 2 diabetes at increased risk for high blood pressure, high cholesterol, kidney disease and eye disease in young adulthood, researchers say.

For Potential Participants

HealthDay Now: Alzheimer’s Drug Approval Harms FDA’s Reputation

In a HealthDay Now interview, we spoke with Dr. G. Caleb Alexander, a professor at Johns Hopkins. He served on the FDA advisory committee that nearly unanimously advised against approving Biogen's controversial new Alzheimer's drug. Dr. Alexander discusses whether the FDA's reputation will take a permanent hit due to the drug's approval despite limited evidence of benefit.

For Potential Participants

Cancer Misinformation Is Common Online, New Study Finds

Researchers warn many cancer articles posted on social media contain potentially harmful misinformation.

For Potential Participants

AHA News: Determined to Ignore the Warning Signs, He's Put That Same Determination Into Heart Attack Recovery

Determined to Ignore the Warning Signs, He's Put That Same Determination Into Heart Attack Recovery

For Potential Participants

Improved Air Quality Boosts Brain Health and Cuts Dementia Risk

Reducing air pollution can significantly lower the risk of dementia and Alzheimer's disease, according to several new studies.

For Potential Participants

AHA News: Olympians Push the Physical Limits of Humankind, But What Limits Humans?

To be an elite athlete, it helps to have good genes. But that's not all it takes.

For Potential Participants

Can COVID Transmit Easily on Crowded School Buses?

Simple mitigation strategies can protect school bus riders from getting COVID-19 on board, researchers say.

For Potential Participants

HealthDay Now: Experts Weigh In On Alzheimer's Drug Controversy

In a HealthDay Now interview, Mabel Jong heard from experts with inside knowledge on the FDA's controversial approval of aducanumab. First up is Dr. G. Caleb Alexander, a professor at Johns Hopkins who served on the FDA advisory committee that nearly unanimously advised against approving Biogen's controversial new Alzheimer's drug. Then, a conversation between Dr. Anton Porsteinsson, a principal investigator for the drug trial, and Dr. Ken Lin, a primary care physician who, like most clinicians surveyed in a new poll, has his concerns and has said he will not prescribe the new drug.

For Potential Participants

Women With Recurrent UTIs Fearful About Antibiotic Overuse, Study Finds

Women with recurrent UTIs say they're frustrated with doctors for not suggesting nonantibiotic treatments.

For Potential Participants

Breastfed Babies Have Healthier Blood Pressure as Kids, Study Finds

Children who are breastfed, even for a short time, have lower blood pressure than those who only receive formula, researchers say.

For Potential Participants

How Long Do People Want to Live?

Preferred life expectancy is significantly impacted by fears over dementia and chronic pain, researchers say.

For Potential Participants

Reading, Writing & Puzzles May Significantly Delay Alzheimer's, Study Finds

Activities that keep your brain active as you age may ward off dementia by up to 5 years, researchers say.

For Potential Participants

Most Romantic Couples Started Out as Friends, Study Finds

Finding a romantic partner through friendship first is more popular than meeting at a party or online, researchers say

Find trials near you

Want more information about clinical trials near you?

Register to get notifications about clinical trials in your area.
Register to Receive Updates